Intriguingly, upreguation of Akt signaling was reported to contribute to the chemoresistance to cisplatin and docetaxel in lung cancer cell lines, and use of LY294002, a PI3K/Akt inhibitor, showed synergy with docetaxel. Here, AKT1 is linked to lung cancer.